• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在观察其他器官癌症期间诊断出的胰腺导管腺癌的自然病史。

Natural History of Pancreatic Ductal Adenocarcinoma Diagnosed During Observation of Other Organ Cancers.

作者信息

Okagawa Yutaka, Kondo Tomohiro, Tsuji Yasushi, Takayama Toshizo, Oiwa Shutaro, Yoshida Masahiro, Ihara Hideyuki, Sumiyoshi Tetsuya, Hirayama Michiaki, Kondo Hitoshi

机构信息

Department of Gastroenterology, Tonan Hospital, Sapporo, Hokkaido, Japan.

Department of Clinical Oncology, Tonan Hospital, Sapporo, Hokkaido, Japan.

出版信息

Am J Case Rep. 2019 Jul 23;20:1080-1084. doi: 10.12659/AJCR.917197.

DOI:10.12659/AJCR.917197
PMID:31335860
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6668584/
Abstract

BACKGROUND Pancreatic ductal adenocarcinoma (PDAC) is a rapidly progressive malignancy that exhibits an extremely poor prognosis, with most cases diagnosed at an advanced stage. To date, few reports have explored the natural history of PDAC, and the period leading up to the detection of PDAC as a tumor with contrast-enhanced computed tomography (CECT) remains unclear. Here, we report 3 PDAC cases diagnosed incidentally by repeating imaging examinations during observation of other organ cancers. CASE REPORT Two patients were undergoing postoperative follow-up for colorectal cancer; owing to the elevation of serum CA19-9 or dilatation of the main pancreatic duct, both cases were finally diagnosed with PDAC. Another patient was administered neoadjuvant chemotherapy for a gastrointestinal stromal tumor; the fluorodeoxyglucose uptake in the pancreas with fluorodeoxyglucose positron emission tomography for the treatment assessment led to the diagnosis of PDAC. All patients underwent frequent CECT for assessment of other diseases, and PDAC became visible with CECT within 3-4 months of the appearance of indirect findings of PDAC. CONCLUSIONS The period leading up to the detection of PDAC as a tumor with CECT was approximately 3-4 months. These cases suggest that additional imaging examinations should be performed when the indirect findings of PDAC are noted. This report adds value to the literature by elucidating the natural course of PDAC.

摘要

背景

胰腺导管腺癌(PDAC)是一种进展迅速的恶性肿瘤,预后极差,大多数病例在晚期才被诊断出来。迄今为止,很少有报告探讨PDAC的自然病史,并且在通过对比增强计算机断层扫描(CECT)检测到PDAC作为肿瘤之前的时间段仍不清楚。在此,我们报告3例在观察其他器官癌症期间通过重复影像学检查偶然诊断出的PDAC病例。病例报告:两名患者正在接受结肠癌术后随访;由于血清CA19-9升高或主胰管扩张,这两例最终均被诊断为PDAC。另一名患者因胃肠道间质瘤接受新辅助化疗;用于治疗评估的氟脱氧葡萄糖正电子发射断层扫描显示胰腺摄取氟脱氧葡萄糖,从而诊断为PDAC。所有患者均因评估其他疾病而频繁接受CECT检查,在出现PDAC间接征象后的3-4个月内,PDAC通过CECT变得可见。结论:通过CECT检测到PDAC作为肿瘤之前的时间段约为3-4个月。这些病例表明,当注意到PDAC的间接征象时,应进行额外的影像学检查。本报告通过阐明PDAC的自然病程为文献增添了价值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3379/6668584/c3581aafb8a1/amjcaserep-20-1080-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3379/6668584/3549b044bfb4/amjcaserep-20-1080-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3379/6668584/9a8836763682/amjcaserep-20-1080-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3379/6668584/c3581aafb8a1/amjcaserep-20-1080-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3379/6668584/3549b044bfb4/amjcaserep-20-1080-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3379/6668584/9a8836763682/amjcaserep-20-1080-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3379/6668584/c3581aafb8a1/amjcaserep-20-1080-g003.jpg

相似文献

1
Natural History of Pancreatic Ductal Adenocarcinoma Diagnosed During Observation of Other Organ Cancers.在观察其他器官癌症期间诊断出的胰腺导管腺癌的自然病史。
Am J Case Rep. 2019 Jul 23;20:1080-1084. doi: 10.12659/AJCR.917197.
2
Computerized tomography scan in pre-diagnostic pancreatic ductal adenocarcinoma: Stages of progression and potential benefits of early intervention: A retrospective study.计算机断层扫描在胰腺导管腺癌的诊断前:进展阶段和早期干预的潜在益处:一项回顾性研究。
Pancreatology. 2020 Oct;20(7):1495-1501. doi: 10.1016/j.pan.2020.07.410. Epub 2020 Aug 11.
3
CT Abnormalities of the Pancreas Associated With the Subsequent Diagnosis of Clinical Stage I Pancreatic Ductal Adenocarcinoma More Than 1 Year Later: A Case-Control Study.1 年以上后临床诊断为 I 期胰腺导管腺癌时与胰腺相关的 CT 异常:病例对照研究。
AJR Am J Roentgenol. 2021 Dec;217(6):1353-1364. doi: 10.2214/AJR.21.26014. Epub 2021 Jun 23.
4
Utility of serum CA19-9 levels in the diagnosis of pancreatic ductal adenocarcinoma in an endoscopic ultrasound referral population.血清CA19-9水平在内镜超声转诊人群中诊断胰腺导管腺癌的效用。
J Gastrointest Cancer. 2014 Mar;45(1):74-9. doi: 10.1007/s12029-013-9563-x.
5
Comparing prognostic factors of Glut-1 expression and maximum standardized uptake value by FDG-PET in patients with resectable pancreatic cancer.比较可切除胰腺癌患者中 Glut-1 表达和 FDG-PET 最大标准化摄取值的预后因素。
Pancreatology. 2020 Sep;20(6):1205-1212. doi: 10.1016/j.pan.2020.07.407. Epub 2020 Aug 3.
6
Visual enhancement pattern during the delayed phase of enhanced CT as an independent prognostic factor in stage IV pancreatic ductal adenocarcinoma.增强 CT 延迟期的视觉增强模式是 IV 期胰腺导管腺癌的独立预后因素。
Pancreatology. 2020 Sep;20(6):1155-1163. doi: 10.1016/j.pan.2020.07.009. Epub 2020 Jul 28.
7
Usefulness of F-fluorodeoxyglucose positron emission tomography/computed tomography for predicting the prognosis and treatment response of neoadjuvant therapy for pancreatic ductal adenocarcinoma.氟[18F]脱氧葡萄糖正电子发射断层扫描/计算机断层扫描预测胰腺导管腺癌新辅助治疗的预后和治疗反应的价值。
Cancer Med. 2020 Jun;9(12):4059-4068. doi: 10.1002/cam4.3044. Epub 2020 Apr 12.
8
Adding Delayed Phase Images to Dual-Phase Contrast-Enhanced CT Increases Sensitivity for Small Pancreatic Ductal Adenocarcinoma.添加延迟相图像可提高双期增强 CT 对小胰腺导管腺癌的敏感性。
AJR Am J Roentgenol. 2021 Oct;217(4):888-897. doi: 10.2214/AJR.20.25430. Epub 2021 Mar 24.
9
Assessment of tumor heterogeneity: Differentiation of periampullary neoplasms based on CT whole-lesion histogram analysis.肿瘤异质性评估:基于 CT 全病变直方图分析的壶腹周围肿瘤鉴别诊断。
Eur J Radiol. 2019 Jun;115:1-9. doi: 10.1016/j.ejrad.2019.03.021. Epub 2019 Mar 30.
10
Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.术前 CEA 和 CA 19-9 是可切除性胰腺导管腺癌患者生存的预后标志物——一项回顾性肿瘤标志物预后研究。
Int J Surg. 2013;11(10):1067-72. doi: 10.1016/j.ijsu.2013.10.005. Epub 2013 Oct 23.

引用本文的文献

1
Analysis of Progression Time in Pancreatic Cancer including Carcinoma In Situ Based on Magnetic Resonance Cholangiopancreatography Findings.基于磁共振胰胆管造影结果对包括原位癌在内的胰腺癌进展时间的分析。
Diagnostics (Basel). 2021 Oct 9;11(10):1858. doi: 10.3390/diagnostics11101858.

本文引用的文献

1
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
2
The impact of a history of cancer on pancreatic ductal adenocarcinoma survival.癌症病史对胰腺导管腺癌生存率的影响。
United European Gastroenterol J. 2018 Jul;6(6):888-894. doi: 10.1177/2050640618765505. Epub 2018 Apr 30.
3
New developments in the early diagnosis of pancreatic cancer.
胰腺癌早期诊断的新进展
Expert Rev Gastroenterol Hepatol. 2017 Feb;11(2):149-156. doi: 10.1080/17474124.2017.1271323. Epub 2016 Dec 20.
4
Time to Progression of Pancreatic Cancer: Evaluation with Multi-Detector Computed Tomography.胰腺癌进展时间:多层螺旋计算机断层扫描评估
J Gastrointest Cancer. 2017 Jun;48(2):164-169. doi: 10.1007/s12029-016-9876-7.
5
Modifiable and non-modifiable risk factors for pancreatic cancer: A review.可改变和不可改变的胰腺癌风险因素:综述。
Cancer Lett. 2016 Oct 10;381(1):269-77. doi: 10.1016/j.canlet.2016.07.022. Epub 2016 Jul 25.
6
K-Ras mutation detection in liquid biopsy and tumor tissue as prognostic biomarker in patients with pancreatic cancer: a systematic review with meta-analysis.液体活检和肿瘤组织中K-Ras突变检测作为胰腺癌患者的预后生物标志物:一项荟萃分析的系统评价
Med Oncol. 2016 Jul;33(7):61. doi: 10.1007/s12032-016-0777-1. Epub 2016 May 25.
7
Value of EUS in early detection of pancreatic ductal adenocarcinomas in patients with intraductal papillary mucinous neoplasms.EUS 在早期检测伴有胰管内乳头状黏液性肿瘤的胰腺导管腺癌中的价值。
Endoscopy. 2014 Jan;46(1):22-9. doi: 10.1055/s-0033-1353603. Epub 2013 Nov 11.
8
18-Fluorodeoxyglucose positron emission tomography does not aid in diagnosis of pancreatic ductal adenocarcinoma.18 氟脱氧葡萄糖正电子发射断层扫描对胰腺导管腺癌的诊断没有帮助。
Clin Gastroenterol Hepatol. 2013 Jun;11(6):712-8. doi: 10.1016/j.cgh.2012.12.033. Epub 2013 Jan 22.
9
Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4).吸烟与胰腺癌:国际胰腺癌病例对照研究协作组(Panc4)的分析。
Ann Oncol. 2012 Jul;23(7):1880-8. doi: 10.1093/annonc/mdr541. Epub 2011 Nov 21.
10
Incidence of subsequent pancreatic adenocarcinoma in patients with a history of nonpancreatic primary cancers.有非胰腺原发性癌症病史的患者中后续胰腺腺癌的发病率。
Cancer. 2012 Mar 1;118(5):1244-51. doi: 10.1002/cncr.26414. Epub 2011 Sep 1.